Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2271)	2/27/2008 11:28:05 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

KOOL wasn't helped with the news on their agreement with the Vet.School of U.C. at Davis.<g> The stock is down 4.55% on moderate volume of 37,685 about 0.25x its ADV. bigcharts.marketwatch.com It announced today that its wholly-owned subsidiary, Vantus, has signed a formal agreement with the UC Davis School of Veterinary Medicine's Center for Equine Health and its Stem Cell Regenerative Medicine Group. The two organizations will conduct joint research of methods to enhance the collecting, processing and storing of stem cells from equine cord blood, bone marrow and placental tissue. These cells will be used in the development of therapeutics for the prevention and treatment of orthopedic injuries, such as tendon and ligament injuries, in performance horses. Earlier this month, KOOL announced the creation of Vantus, a laboratory service company focused on the performance equine market, including Thoroughbreds, American Quarter Horses, Arabians and Warm Bloods. KOOL's MarrowXpress & BioArchive will be used for processing and storage of the stem cells. The regulatory hurdles in the veterinary medicine are relatively low. As a result KOOL expects to realize rapid growth in this business and make it an important contributor to shareholder value. In addition, it looks forward to translating the lessons learned in the equine market to stem cell-based therapies for orthopedic injuries in humans. KOOL's short ratio is around 17x its ADV. Will see if it the support at the $1.50 level holds or it it will retest the Jan 9 L at $1.35 <g> bigcharts.marketwatch.com Bernard